{"ok":true,"entity":{"id":"dexcom","name":"Dexcom","entityType":"company","officialName":"DexCom, Inc.","canonicalName":"Dexcom","displayName":"Dexcom","category":"連続血糖測定（CGM）医療機器企業","shortDescription":"カリフォルニア州サンディエゴの連続血糖測定（CGM）企業（Nasdaq: DXCM、1999年設立）。Dexcom G7、最大15.5日装着のG7 15 Day、市販（OTC）向けStelo等を提供する。2026年第2四半期の売上高は13億800万ドル（前年同期比13%増）で、CEOはJake Leach（2026年1月就任）。G7をめぐる集団訴訟やFDAのClass Iリコールも報じられている（2026年10月時点）。","primaryCluster":"medical-device","parentEntity":null,"verificationStatus":"draft","website":"https://www.dexcom.com/","updatedAt":"2026-10-13T05:36:43.320Z","secondaryClusters":[],"alias":["デクスコム","DexCom"],"searchKeywords":["Dexcom","デクスコム","CGM","連続血糖測定","Dexcom G7","Stelo","糖尿病","サンディエゴ"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}